The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Soumaya Labidi
No Relationships to Disclose
 
Aida Salehi
No Relationships to Disclose
 
Parvaneh Fallah
No Relationships to Disclose
 
Vincent G. Morin
No Relationships to Disclose
 
Meredith Li
No Relationships to Disclose
 
Stephan Probst
Consulting or Advisory Role - Novartis Canada Pharmaceuticals Inc
 
Cristiano Ferrario
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Knight Pharmaceuticals; Merck; Novartis; Pfizer; Roche Canada
Consulting or Advisory Role - AstraZeneca; Merck; Novartis; Roche
Speakers' Bureau - AstraZeneca; Knight Therapeutics; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bicycle Therapeutics (Inst); Immunomedics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Zymeworks (Inst)
Expert Testimony - Seattle Genetics/Astellas
 
April A. N. Rose
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; EMD Serono
Research Funding - AstraZeneca Canada (Inst); Canada Foundation for Innovation; Canadian Cancer Society; Canadian Institutes of Health Research (CIHR); Conquer Cancer Foundation; Jewish General Hospital Foundation; Merck (Inst); Pfizer (Inst); Seagen (Inst); TransMedTech Institute